One-Cycle BE500P Seems Safe for High-Risk Early Testicular Cancer

MONDAY, Jan. 6, 2020 -- For high-risk stage 1 nonseminoma germ cell tumors of the testis (NSGCTT), one cycle of adjuvant bleomycin, etoposide (500 mg/m ²), and cisplatin (BE500P) is safe, resulting in a two-year malignant recurrence (MR) rate of 1.3...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news